Transmedics Group, INC Form 4 insider transactions

Director Edward M. Basile exercised stock options and sold shares of TransMedics Group, Inc. on May 9, 2025.

Tamer I. Khayal, Chief Commercial Officer of TransMedics Group, sold 2,407 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Waleed Hassanein, President & CEO of TransMedics Group, reports acquisition of restricted stock units and stock options, as well as disposition of common stock held by a revocable trust.

Chief Financial Officer Gerardo Hernandez of TransMedics Group, Inc. reports acquisition of restricted stock units and stock options.

Nicholas Corcoran, SVP of Supply Chain and Operations at TransMedics Group, reported the acquisition of restricted stock units and stock options.

Anil Ranganath, a Senior Vice President at TransMedics Group, reported the acquisition of restricted stock units and a stock option, along with stock acquired through the employee stock purchase plan.

Chief Commercial Officer Tamer Khayal reports acquisition of restricted stock units and stock options in TransMedics Group, Inc.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

TransMedics Group's Chief Financial Officer, Gerardo Hernandez, received stock options and restricted stock units as part of his compensation package.

TransMedics Group's Chief Commercial Officer, Tamer Khayal, exercised stock options and sold shares on December 2, 2024, under a pre-arranged trading plan.

TransMedics Group's Chief Commercial Officer, Tamer Khayal, executed a stock option exercise and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Director Edward M. Basile exercised stock options and sold shares of TransMedics Group, Inc. on November 5, 2024, according to a Form 4 filing.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares on November 1, 2024, according to a recent SEC filing.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares of common stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director James R. Tobin reports gifting shares of TransMedics Group, Inc. to family trusts.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan on September 3, 2024.

Nicholas Corcoran, SVP of Supply Chain and Operations at TransMedics Group, exercised stock options and sold 10,000 shares of common stock on August 27, 2024.

CEO Waleed Hassanein exercised stock options and sold shares of TransMedics Group, Inc. on August 21 and 22, 2024.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock on August 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Anil P. Ranganath, a Senior Vice President at TransMedics Group, reported the sale and acquisition of company stock, including transactions related to tax obligations and an employee stock purchase plan.

James R. Tobin, a director at TransMedics Group, Inc., sold shares of common stock on August 8, 2024.

Director Edward M. Basile exercised stock options and sold shares of TransMedics Group, Inc. on August 6, 2024, according to a Form 4 filing with the SEC.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan on August 1, 2024.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares on July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock on June 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Edward M. Basile of TransMedics Group, Inc. sold 1,193 shares of common stock on June 5, 2024.

Stephen Gordon, CFO of TransMedics Group, exercised stock options and sold shares on June 3, 2024, according to a recent SEC filing.